The pharmaceutical community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 target that’s showing significant promise in clinical trials for managing obesity. Unlike some current weight loss approaches, retatrutide appears to provide a more substantial loss in body mass and benefit metabolic health, particularly